Get the Stockscreener App
8.24
3.91%
0.31
After Hours:
8.24
Lexeo Therapeutics Inc stock is traded at $8.24, with a volume of 256.66K.
It is up +3.91% in the last 24 hours and down -4.85% over the past month.
Lexeo Therapeutics Inc is a a clinical-stage genetic medicines company dedicated to transforming healthcare by applying pioneering science to fundamentally change how disease is treated. Its pipeline consists of candidates targeting patient populations that place significant burden on society and are most amenable to their genetic medicine approach. The Company is focused on preclinical and clinical stage gene therapies, and specifically on hereditary and acquired diseases of high unmet need which is their only business segment.
See More
Previous Close:
$7.93
Open:
$7.92
24h Volume:
256.66K
Relative Volume:
0.89
Market Cap:
$264.49M
Revenue:
-
Net Income/Loss:
$-62.31M
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-16.17%
1M Performance:
-4.85%
6M Performance:
-35.47%
1Y Performance:
+0.00%
1-Day Range:
$7.835
$8.38
1-Week Range:
$7.54
$9.97
52-Week Range:
$7.54
$22.33
Lexeo Therapeutics Inc Stock (LXEO) Company Profile
Name
Lexeo Therapeutics Inc
Sector
Industry
Phone
(212) 547-9879
Address
345 PARK AVENUE SOUTH, NEW YORK
Lexeo Therapeutics Inc Stock (LXEO) Latest News
Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Receives Average Recommendation of "Buy" from Analysts - MarketBeat
Lexeo Therapeutics (NASDAQ:LXEO) Earns Buy Rating from HC Wainwright - MarketBeat
Lexeo shares dip on early data with Alzheimer's gene therapy - pharmaphorum
Lexeo reports positive Alzheimer's drug trial results - Investing.com India
Lexeo reports positive Alzheimer's drug trial results By Investing.com - Investing.com South Africa
Lexeo Therapeutics Announces Positive Interim Data for - GlobeNewswire
How now, tau? ‘Newer science’ shines in Lexeo Alzheimer’s data - BioWorld Online
Lexeo Therapeutics Sees Positive Results for Alzheimer's Disease Treatment - MarketWatch
Lexeo Therapeutics Announces Positive Interim Data for LX1001, First-Ever Gene Therapy to - The Bakersfield Californian
Lexeo Therapeutics Announces Positive Interim Data for LX1001, First-Ever Gene Therapy to Impact the Underlying Genetic Cause of APOE4-Associated Alzheimer’s Disease, at the Clinical Trials on Alzheimer’s Disease (CTAD) Conference - StockTitan
Lexeo Therapeutics’ (LXEO) “Buy” Rating Reiterated at Chardan Capital - Defense World
(LXEO) Investment Analysis - Stock Traders Daily
Novo Holdings A S Trims Position in Lexeo Therapeutics, Inc. (NASDAQ:LXEO) - MarketBeat
Lexeo Therapeutics' (LXEO) "Buy" Rating Reaffirmed at Chardan Capital - MarketBeat
Lexeo Therapeutics to Present New Interim Data from Phase 1/2 Trial of LX1001 at the Clinical Trials on Alzheimer's Disease (CTAD) 2024 Conference - The Manila Times
Lexeo Therapeutics to Present New Interim Data from Phase - GlobeNewswire
Lexeo Therapeutics to Present New Interim Data from Phase 1/2 Trial of LX1001 at the Clinical Trials on Alzheimer’s Disease (CTAD) 2024 Conference - StockTitan
R. Nolan Townsend - Crain's New York Business
(LXEO) Proactive Strategies - Stock Traders Daily
Insider Selling: Lexeo Therapeutics, Inc. (NASDAQ:LXEO) CEO Sells 5,000 Shares of Stock - MarketBeat
Lexeo Therapeutics (NASDAQ:LXEO) Files 8-K Disclosing Change in Directors or Principal Officers - MarketBeat
Long Term Trading Analysis for (LXEO) - Stock Traders Daily
Lexeo Therapeutics' SWOT analysis: gene therapy stock poised for growth - Investing.com India
Novo Holdings A S Reduces Stock Position in Lexeo Therapeutics, Inc. (NASDAQ:LXEO) - MarketBeat
Lexeo Therapeutics' SWOT analysis: gene therapy stock poised for growth By Investing.com - Investing.com UK
Can you now get a good deal on Lexicon Pharmaceuticals Inc’s shares? - US Post News
Aurobindo to acquire 49% stake in GLS Pharma for Rs 22.5 crore - The Economic Times
LXP Industrial Trust (NYSE:LXP) PT Raised to $11.00 at Evercore ISI - Defense World
Lexicon Pharmaceuticals President and COO Jeffrey Wade to step down - The Business Journals
How Analyst Ratings Affect Leap Therapeutics Inc Inc. (LPTX) Price Performance - The InvestChronicle
Quest Partners LLC Acquires 11,597 Shares of LXP Industrial Trust (NYSE:LXP) - Defense World
Financial Analysis: Lexaria Bioscience (NASDAQ:LEXX) & Xeris Biopharma (NASDAQ:XERS) - Defense World
Get in on Lexicon Pharmaceuticals Inc’s (LXRX) buy-in window today! - SETE News
LXP Industrial Trust price target raised to $11 from $10 at Evercore ISI - TipRanks
Investor’s Delight: Lexicon Pharmaceuticals Inc (LXRX) Closes Strong at 1.70, Up 1.80 - The Dwinnex
Objective long/short (LXEO) Report - Stock Traders Daily
Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Receives $22.14 Consensus Price Target from Analysts - MarketBeat
Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Short Interest Update - MarketBeat
Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Given Average Recommendation of “Buy” by Analysts - Defense World
Gene Therapies For Cardiomyopathies Market Growth Anticipated - openPR
The Globe and Mail - The Globe and Mail
Lexeo Therapeutics, Inc. (NASDAQ:LXEO) CEO Richard Nolan Townsend Sells 5,000 Shares - MarketBeat
Lexeo Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewswire
Top investors say Lexeo Therapeutics Inc. (LXEO) ticks everything they need - SETE News
The Lexeo Therapeutics Inc. (LXEO) had a good session last reading, didn’t it? - US Post News
Short Interest in Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Expands By 16.9% - MarketBeat
Trading (LXEO) With Integrated Risk Controls - Stock Traders Daily
Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Receives $22.14 Average Price Target from Analysts - MarketBeat
Chardan Capital Comments on Lexeo Therapeutics, Inc.'s FY2024 Earnings (NASDAQ:LXEO) - MarketBeat
Vanguard Group Inc. Grows Position in Lexeo Therapeutics, Inc. (NASDAQ:LXEO) - MarketBeat
Stifel maintains 'Buy' on Lexeo stock, confident amid trial progress By Investing.com - Investing.com Canada
Lexeo Therapeutics Inc Stock (LXEO) Financials Data
Revenue
Net Income
Cash Flow
EPS
5.11%
0.50%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):